Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked faithfully but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last several shares of mine. The first CytoDyn article of mine, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set away the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire employment interview which I came away with a poor opinion of the company.

Irony of irony, my bad impression of the business enterprise has grown steadily, although the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the expertise and connected intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) plus the very first new drug application endorsement ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with multiple indications and numerous therapies, it has this single remedy in addition to a “broad pipeline of indications” as it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely advantageous therapy in dozens of indications.

Its opening banner on its website (below) shows an active company with diverse interests albeit centered on leronlimab, several disease sorts, multiple publications in addition to multiple delivering presentations.

Might it all be smoke and mirrors? That is a question I have been asking myself from the really beginning of the interest of mine in this particular business. Judging by the multiples of a huge number of various remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *